TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16882893
Drug: Bupivacaine (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (alone or in combination with betamethasone)
Study: 7956538
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of low dosed or low molecular heparin into the contralateral abdominal wall
Study: 7956538
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of low dosed or low molecular heparin into the thigh
Study: 40816
Drug: Phenazepam (0.0025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenazepam (0.0025 mg/kg)
Study: 40816
Drug: Diazepam (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.005 mg/kg)
Study: 20673485
Drug: Post-chemotherapy tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-chemotherapy tumor extent (GTV-T) irradiation
Study: 20673485
Drug: Pre-chemotherapy tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-chemotherapy tumor extent (GTV-T) irradiation
Study: 18397701
Drug: Cinacalcet (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (30 - 180 mg/day)
Study: 4014796
Drug: 5 units
Normalized name: Omnipod GO 15 Units/Day Pods
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 units oxytocin in intravenous infusion throughout the procedure
Study: 21436229
Drug: Mitoxantrone (MITOX)
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitoxantrone (MITOX) monthly (12 mg/m²; maximum 20 mg) combined with 1 g of methylprednisolone (MP) for 6 months followed by interferon beta-1b (IFN) for the last 27 months
Study: 21436229
Drug: Interferon beta-1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1b (IFN) for 3 years combined with 1 g of methylprednisolone (MP) monthly for the first 6 months
Study: 17511904
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment using modified Luque III instrumentation
Study: 15356403
Drug: Levormeloxifene (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levormeloxifene (5 mg/kg/day)
Study: 15356403
Drug: Levormeloxifene (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levormeloxifene (0.2 mg/kg/day)
Study: 2033963
Drug: CNS prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS prophylaxis with intermediate dose methotrexate (MTX) and intrathecal MTX
Study: 6803279
Drug: Imipramine (50‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (50‐200 mg/day)
Study: 6803279
Drug: Nortriptyline with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline with perphenazine (8‐16 mg/day)
Study: 14731120
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon (IFN)-alpha 2b (10 MU/m2) thrice/weekly for 6 months
Study: 8311217
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine gel applied to Filshie clips
Study: 8311217
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no lignocaine gel)
Study: 6779334
Drug: diazepam 2
Normalized name: diazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 2 mg
Study: 6134543
Drug: diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 5 mg
Study: 31334703
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg/day and EPA 1,800 mg/day
Study: 31334703
Drug: rosuvastatin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 2.5 mg/day
Study: 21857944
Drug: Olanzapine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (10 mg/day) for three days prior to oGTT testing
Study: 31075442
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg oral)
Study: 14756383
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg oral)
Study: 11466256
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three drugs (Timolol, Betaxolol, Carteolol)
Study: 3360173
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg norethisterone (NE)
Study: 26330412
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Ezetimibe/simvastatin and Simvastatin)
Study: 21205113
Drug: IV fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV fructose (0.3 mg/kg)
Study: 8824693
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg spirapril (chronic treatment)
Study: 8824693
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg spirapril (first dose)
Study: 8824693
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg spirapril
Study: 8824693
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg spirapril
Study: 3918993
Drug: Imipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (50 mg/day, increased to 100-300 mg/day)
Study: 17065257
Drug: Bivalent meningococcal
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent meningococcal outer membrane vesicle vaccine (B:4:P1.19,15 and B:4:P1.7‐2,4)
Study: 17065257
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (two doses of hepatitis A and one of conjugated meningococcal serogroup C vaccine on a 0-1-6 month schedule)
Study: 16263208
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement (soy, isoflavones, lycopene, silymarin, antioxidants)
Study: 10450255
Drug: Clozapine add-on
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine add-on treatment
Study: 395525
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg danazol daily for 100 days
Study: 30261902
Drug: Combination ART
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ART
Study: 29608685
Drug: Dolutegravir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir monotherapy
Study: 22156542
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) at 67 μg/kg/day
Study: 22156542
Drug: Untreated control
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated control (UC) group at 33 μg/kg/day
Study: 9891195
Drug: Other laxatives
Normalized name: LAXATIVES,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other laxatives (mainly lactulose)
Study: 8022533
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms triiodothyronine (T3) administered orally for 3 consecutive days
Study: 1079213
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg daily
Study: 1096901
Drug: Indometacin 100
Normalized name: Indometacin 100 mg rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin 100 mg daily
Study: 12500022
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate (200 mg once daily)
Study: 8380266
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium 4 mg, 4 times daily for 8 weeks
Study: 3298387
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of bovine superoxide dismutase (SOD) at a dosage of 0.25 mg/kg
Study: 24957950
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination (Vaxigrip)
Study: 20540666
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g daily EPA
Study: 20540666
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g daily DHA
Study: 10854812
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg orally, qds for 10 days
Study: 30117300
Drug: Moxidectin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxidectin (4 mg, 8 mg, 16 mg, 24 mg, or 36 mg)
Study: 27258494
Drug: Long-term dual
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term dual antiplatelet therapy (DAT) (>12 months)
Study: 27258494
Drug: Short-term dual
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term dual antiplatelet therapy (DAT) (<12 months)
Study: 27258494
Drug: Clopidogrel therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel therapy for >12 months
Study: 12852712
Drug: IV linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV linezolid 600 mg every 12 hours for 7 to 21 days
Study: 12852712
Drug: IV vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV vancomycin 1 g every 12 hours for 7 to 21 days
Study: 8853535
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy (radiation and chemotherapy)
Study: 3909471
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 500 mg + codeine phosphate 30 mg
Study: 6373441
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 500 mg
Study: 27255456
Drug: Hydroalcoholic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroalcoholic extract of Tribulus terrestris (1000 mg/d)
Study: 22789657
Drug: Online cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive behavior therapy (CBT) with minimal therapist contact
Study: 18947350
Drug: Comparative judgments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparative judgments (e.g., indicating preference between two stimuli in different domains, comparing wild animals, comparing animals' physical attributes, estimating similarity between objects)
Study: 7674270
Drug: First-line combination
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line combination therapy
Study: 23611083
Drug: TMT root
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMT root treatment
Study: 21936251
Drug: Probiotic yoghurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yoghurt (200 g daily containing Lactobacillus acidophilus La5 and Bifidobacterium animalis BB12, 10(7) CFU g(‐1) for each)
Study: 2227611
Drug: Estriol 4
Normalized name: ESTRIOL 49.5 g in 50 g NOT APPLICABLE POWDER [AX Pharmaceutical Corp]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol 4 mg once daily
Study: 31578015
Drug: Nadroparin 1,900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin 1,900 IU (0.2 mL) intravenously (IV group)
Study: 31578015
Drug: Nadroparin 3,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin 3,800 IU (0.4 mL) subcutaneously (SC group)
Study: 20719303
Drug: Low-dose endotoxin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose endotoxin
Study: 25315260
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day ALN
Study: 21817116
Drug: Intraperitoneal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal administration of baicalein by repeated injection
Study: 19657202
Drug: AFA breathing
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFA breathing therapy
Study: 14976885
Drug: Integrative Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Chinese and Western medicine (ICWM) therapeutic program
Study: 9024142
Drug: Daily drinkers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily drinkers (>= 7 drinks per week)
Study: 8329004
Drug: L-glutamine monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamine monofluorophosphate (G-MFP) tablets
Study: 8329004
Drug: L-glutamine monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamine monofluorophosphate (G-MFP) powder for oral use
Study: 16281491
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg + aspirin 325 mg (group 1)
Study: 16281491
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg + aspirin 325 mg (group 2)
Study: 10464060
Drug: L-NMMA (13.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (13.5 mg/kg)
Study: 10464060
Drug: NO inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO inhalation (30 p.p.m)
Study: 19890262
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (placebo)
Study: 8751032
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg q.i.d. for 6 days)
Study: 631030
Drug: Hydergine (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydergine (4.5 mg daily)
Study: 23985625
Drug: Peramivir 600
Normalized name: peramivir 600 mg in 60 mL INTRAVENOUS SOLUTION [Rapivab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peramivir 600 mg once daily
Study: 20613645
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CON) performing only technical preparation.
Study: 18410584
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg melatonin (n = 24)
Study: 12000008
Drug: Pentoxifylline (Ptx)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (Ptx) 500 mg l(‐1) added to prime solution
Study: 12000008
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received only prime solution
Study: 8670316
Drug: rHuIL‐1Ra 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuIL‐1Ra 20 mg administered once, 3 times, or 7 times per week
Study: 8670316
Drug: rHuIL‐1Ra 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuIL‐1Ra 70 mg administered once, 3 times, or 7 times per week
Study: 8670316
Drug: rHuIL‐1Ra 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuIL‐1Ra 200 mg administered once, 3 times, or 7 times per week
Study: 19934090
Drug: Haemoglobin (Hb)
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemoglobin (Hb) of 9-10 g/dl
Study: 19934090
Drug: Haemoglobin (Hb)
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemoglobin (Hb) > 13 g/dl
Study: 15860488
Drug: Paclitaxel 35
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 35 mg/m2/24 h continuously infused over 96 h (days 1-4) every 21 days for up to six courses
Study: 10076743
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy (CBT) and medication simultaneously (n = 9)
Study: 10076743
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy (CBT) only (n = 6)
Study: 10076743
Drug: Medication while
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication while on a wait-list for CBT (n = 6)
Study: 10076743
Drug: Subsequent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subsequent administration of CBT to those groups on the wait-list
Study: 9395604
Drug: High-density negative
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-density negative ion treatment (2.7 x 10(6) ions/cm3)
Study: 9395604
Drug: Low-density negative
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-density negative ion treatment (1 x 10(4) ions/cm3)
Study: 1954643
Drug: Slow-K tablets
Normalized name: Slow-Fe
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Slow-K tablets
Study: 30223315
Drug: Intraperitoneal dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraperitoneal dexamethasone 8 mg (IP)
Study: 9292561
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of 750 mg of vancomycin administered 6 to 12 hours before the procedure
Study: 17707753
Drug: Adjuvanted vaccine
Normalized name: PIKA-adjuvanted vaccine composition
DrugBank: PIKA rabies vaccine (DB17963)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted vaccine (3.8 microg)
Study: 17707753
Drug: Adjuvanted vaccines
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted vaccines (all doses)
Study: 17707753
Drug: Non-adjuvanted vaccines
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccines (all doses)
Study: 10973155
Drug: All vaccine
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All vaccine formulations
Study: 22381809
Drug: Tacrolimus monotherapy
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus monotherapy
Study: 11589769
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (CAP)
Study: 8201130
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light for 1 h daily for 2 weeks
Study: 21199175
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg intravenously)
Study: 23530729
Drug: Prostaglandin E₂
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin E₂ gel
Study: 20419525
Drug: Olanzapine for
Normalized name: Olanzapine for Extended-Release Injectable Suspension
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine for adjunctive treatment of anorexia nervosa
Study: 16909188
Drug: Oral trimethoprim
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral trimethoprim (TMP) 5 mg/kg
Study: 16909188
Drug: Oral trimethoprim
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral trimethoprim (TMP) 10 mg/kg
Study: 16909188
Drug: Oral trimethoprim
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral trimethoprim (TMP) 20 mg/kg
Study: 16909188
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of oral TMP 5 mg/kg
Study: 16909188
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of oral TMP 10 mg/kg
Study: 15072506
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg/day (n = 15)
Study: 1568369
Drug: Metadoxine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metadoxine (500 mg twice a day)
Study: 11870439
Drug: Standard-dose FDT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose FDT (S400, n=25)
Study: 19508679
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg rhTSH
Study: 7909705
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 mg) plus Metoprolol (50 mg)
Study: 7909705
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg) plus Atenolol (50 mg)
Study: 3781700
Drug: Ambroxol (1.5‐2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (1.5‐2.0 mg/kg body weight orally)
Study: 25338443
Drug: Comprehensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive treatment group
Study: 28629344
Drug: ONO-5334 100
Normalized name: ONO-5334
DrugBank: ONO-5334 (DB19206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-5334 100 mg QD
Study: 24038152
Drug: ONO-5334 300
Normalized name: ONO-5334
DrugBank: ONO-5334 (DB19206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-5334 300 mg QD
Study: 28629344
Drug: ONO-5334 50
Normalized name: ONO-5334
DrugBank: ONO-5334 (DB19206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-5334 50 mg BID
Study: 28629344
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of ONO-5334 50 mg BID vs. 100 mg QD
Study: 11081529
Drug: Post-treatment isoniazid
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment isoniazid prophylaxis
Study: 1588829
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/d and 40 mg/d)
Study: 1588829
Drug: Fenofibrate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (400 mg/d)
Study: 3014473
Drug: Oka-strain live
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain Injection [Varivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oka-strain live varicella vaccine
Study: 29224964
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of combined MMR and one dose of monovalent varicella vaccine (MMR+V)